AzaSite (azithromycin ophthalmic solution) 1% has been approved by the FDA.
New drop to clear conjunctivitis By the third quarter of 2007, a new treatment for bacterial conjunctivitis will be available from Inspire Pharmaceuticals. AzaSite (azithromycin ophthalmic solution) 1% has been approved by the FDA and, according to the manufacturer, will offer patients a reduced dosing regimen compared with other available products for treating the condition. One drop twice-daily for two days, followed by one drop once-daily for the next five days, for a total of nine drops in the affected eye, is the recommended dosing schedule.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.